Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Invested Capital (2016 - 2025)

Historic Invested Capital for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $1.8 billion.

  • Integra Lifesciences Holdings' Invested Capital fell 2243.54% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 2243.54%. This contributed to the annual value of $2.3 billion for FY2024, which is 241.8% down from last year.
  • As of Q3 2025, Integra Lifesciences Holdings' Invested Capital stood at $1.8 billion, which was down 2243.54% from $1.8 billion recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' Invested Capital ranged from a high of $2.6 billion in Q4 2022 and a low of $1.8 billion during Q3 2025
  • Moreover, its 5-year median value for Invested Capital was $2.4 billion (2021), whereas its average is $2.3 billion.
  • As far as peak fluctuations go, Integra Lifesciences Holdings' Invested Capital soared by 963.96% in 2021, and later crashed by 2255.52% in 2025.
  • Integra Lifesciences Holdings' Invested Capital (Quarter) stood at $2.5 billion in 2021, then rose by 2.01% to $2.6 billion in 2022, then fell by 8.39% to $2.4 billion in 2023, then fell by 2.42% to $2.3 billion in 2024, then dropped by 23.07% to $1.8 billion in 2025.
  • Its last three reported values are $1.8 billion in Q3 2025, $1.8 billion for Q2 2025, and $2.3 billion during Q1 2025.